Galera Therapeutics, Inc. (OTC:GRTX) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Nancy Chang Other companies: Immix Biopharma, Inc. (Independent Director · Since at least Sep 8, 2025); W&T Offshore, Inc. (Director · Since at least Apr 28, 2023); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); SciClone Pharmaceuticals Inc (Director · Sep 17, 2013 – Oct 13, 2017 · Past); Charles River Laboratories International, Inc. (Director · Oct 24, 2007 – May 7, 2010 · Past); Tanox Inc (Director · Dec 31, 2005 – Nov 2, 2006 · Past) | Director · Since at least Dec 30, 2024 |
| Lawrence M. Alleva Other companies: Mersana Therapeutics Inc (Director · Since at least Sep 5, 2017); Bright Horizons Family Solutions Inc. (Board Member · Since at least May 12, 2016); Adaptimmune Therapeutics PLC (Chairman and Non-Executive Director · Since at least Jan 1, 2016); Tesaro Inc (Director · Jun 1, 2016 – Jan 22, 2019 · Past); Synlogic Inc (Director · Sep 30, 2015 – Jun 29, 2016 · Past) | Director · Since at least Nov 6, 2019 |
| Emmett Cunningham Other companies: NovaBridge Biosciences (Director · Since at least Mar 18, 2026); Annexon, Inc. (Director · Jul 23, 2020 – Jul 23, 2020 · Past); Lumos Pharma Inc (Director · Mar 18, 2020 – Apr 3, 2020 · Past); Venus Concept Inc (Director · Oct 11, 2017 – Oct 11, 2017 · Past) | Director · Nov 6, 2019 – Jun 14, 2023 · Past |
| Jennifer Evans Stacey Other companies: Neogen Corporation (Chief Legal Officer · Since at least Apr 8, 2026); Context Therapeutics Inc. (Independent Director · Since at least Oct 19, 2021); Antares Pharma Inc (SVP, General Counsel & Secty · May 29, 2014 – May 28, 2015 · Past); Auxilium Pharmaceuticals Inc (Executive VP & General Counsel · Jun 6, 2006 – Feb 28, 2011 · Past) | See Remarks · Oct 8, 2021 – Feb 25, 2023 · Past |
| Arthur Fratamico Other companies: Panbela Therapeutics, Inc. (Director · Dec 1, 2020 – Mar 27, 2023 · Past); Vitae Pharmaceuticals Inc (Chief Business Officer · Sep 24, 2014 – Oct 24, 2016 · Past); Flexion Therapeutics Inc (Chief Business Officer · Feb 11, 2014 – Feb 11, 2014 · Past) | Chief Business Officer · Nov 6, 2019 – Jan 26, 2021 · Past |
| Michael Powell Other companies: Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Checkmate Pharmaceuticals Inc (Director · Aug 6, 2020 – May 31, 2022 · Past); Synlogic Inc (Director · Dec 29, 2017 – Jun 5, 2019 · Past) | Director · Nov 6, 2019 – Jun 14, 2023 · Past |
| Chris Degnan Other companies: UroGen Pharma Ltd. (Chief Financial Officer · Since at least Oct 8, 2024); Verrica Pharmaceuticals Inc. (Chief Financial Officer · Jun 14, 2018 – Feb 28, 2019 · Past) | Chief Financial Officer · Nov 6, 2019 – Mar 13, 2023 · Past |
| Eugene Kennedy Other companies: Aprea Therapeutics, Inc. (Chief Medical Advisor · Since at least Oct 16, 2026); Lumos Pharma Inc (Chief Medical Officer · Nov 13, 2017 – Feb 1, 2021 · Past) | Chief Medical Officer · Sep 1, 2022 – Feb 25, 2023 · Past |
| Caroline Code Other companies: Obsidian Therapeutics, Inc. (VP Corporate Development and Investor Relations · Since at least Aug 5, 2026) | VP Corporate Development & Investor Relations · Since at least Apr 14, 2026 |
| Linda West Other companies: Context Therapeutics Inc. (Independent Director · Since at least Oct 19, 2021) | Director · Mar 31, 2020 – Jul 1, 2023 · Past |
| Mark J. Bachleda Other companies: Lyell Immunopharma, Inc. (Director · Since at least Jun 9, 2025) | Chief Commercial Officer · Oct 8, 2021 – Mar 16, 2023 · Past |
| Robert Beardsley Other companies: Arbutus Biopharma Corporation (Director · Since at least Feb 24, 2025) | Chief Operating Officer · Nov 6, 2019 – Feb 25, 2023 · Past |
| Jason Fuller | Director · Nov 6, 2019 – Nov 6, 2019 · Past |
| Joel F Sussman | Chief Accounting Officer · Since at least Nov 6, 2019 |
| Jon T Holmlund | Chief Medical Officer · Nov 6, 2019 – Feb 28, 2022 · Past |
| Kevin G Lokay | Director · Since at least Nov 6, 2019 |
| Mel Sorensen | President and CEO, Director · Since at least Nov 6, 2019 |
| Michael R Friedman | Director · Since at least Dec 30, 2024 |